Heron Therapeutics Inc (HRTX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Heron Therapeutics Inc (HRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012212
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heron Therapeutics Inc (Heron), formerly A.P. Pharma, Inc., is a biotechnology company that uses its proprietary polymer-based drug delivery platform to develop novel, patient-focused therapeutic products for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company’s first commercial product Sustol is an extended-release injection indicated in combination with other antiemetics in adults for the prevention of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Heron’s developmental pipeline includes HTX-011 for post-operative pain management and Cinvanti (HTX-019) for chemotherapy-induced nausea and vomiting (CINV) prevention. Heron is headquartered in San Diego, California, the US.

Heron Therapeutics Inc (HRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heron Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Equity Offering 12
Heron Therapeutics Prices Public Offering of Shares for USD150 Million 12
Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 14
Heron Therapeutics Raises USD137 Million in Public Offering of Shares 16
Heron Therapeutics Raises USD55.8 Million in Public Offering of Shares 18
Heron Therapeutics Raises USD7 Million in Private Placement of Warrants 20
A.P. Pharma Completes Public Offering Of Shares For US$60 Million 21
A.P. Pharma Completes Private Placement Of Common Stock For US$54 Million 23
A.P. Pharma Completes Private Placement Of Units For US$24 Million 24
Debt Offering 25
A.P. Pharma Completes Intial Closing Of Private Placement Of Convertible Notes For US$1.5 Million 25
Heron Therapeutics Inc – Key Competitors 26
Heron Therapeutics Inc – Key Employees 27
Heron Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 06, 2017: Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 29
Aug 09, 2017: Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 30
May 10, 2017: Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 31
Feb 23, 2017: Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress 32
Nov 08, 2016: Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate Progress 33
Aug 08, 2016: Heron Therapeutics Reports Second Quarter 2016 Financial Results and Recent Corporate Progress 34
May 05, 2016: Heron Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Progress 35
Feb 19, 2016: Heron Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Progress 36
Corporate Communications 37
Apr 24, 2017: Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance 37
Jun 22, 2016: Heron Therapeutics Announces Appointment of Christian Waage to Board of Directors 38
Clinical Trials 39
Jan 04, 2017: Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty 39
Jan 04, 2017: Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies 40
Sep 08, 2016: Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek 2016 41
Aug 29, 2016: Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek 2016 43
Aug 01, 2016: Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative Pain 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heron Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Heron Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heron Therapeutics Prices Public Offering of Shares for USD150 Million 12
Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 14
Heron Therapeutics Raises USD137 Million in Public Offering of Shares 16
Heron Therapeutics Raises USD55.8 Million in Public Offering of Shares 18
Heron Therapeutics Raises USD7 Million in Private Placement of Warrants 20
A.P. Pharma Completes Public Offering Of Shares For US$60 Million 21
A.P. Pharma Completes Private Placement Of Common Stock For US$54 Million 23
A.P. Pharma Completes Private Placement Of Units For US$24 Million 24
A.P. Pharma Completes Intial Closing Of Private Placement Of Convertible Notes For US$1.5 Million 25
Heron Therapeutics Inc, Key Competitors 26
Heron Therapeutics Inc, Key Employees 27
Heron Therapeutics Inc, Other Locations 28

★海外企業調査レポート[Heron Therapeutics Inc (HRTX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tokyo Gas Co Ltd (9531):電力:M&Aディール及び事業提携情報
    Summary Tokyo Gas Co Ltd (Tokyo Gas) is a gas utility that produces, supplies and markets liquefied natural gas (LNG). It also produces, supplies and sells electricity. Tokyo Gas also has overseas upstream, midstream and downstream businesses. It provides engineering solutions, gas appliances and ga …
  • The Bangchak Petroleum PCL (BCP):石油・ガス:M&Aディール及び事業提携情報
    Summary The Bangchak Petroleum PCL (Bangchak) is an oil and gas company. It carries out import of crude oil from both indigenous and overseas sources, and refines it into finished petroleum products. Its refinery produces gasoline, gasohol and diesel products. The company markets its petroleum produ …
  • PT. Asuransi Jiwasraya (Persero):企業の戦略・SWOT・財務分析
    PT. Asuransi Jiwasraya (Persero) - Strategy, SWOT and Corporate Finance Report Summary PT. Asuransi Jiwasraya (Persero) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Berthold Technologies GmbH & Co. KG:企業の戦略的SWOT分析
    Berthold Technologies GmbH & Co. KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • CEFC China Energy Co Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary CEFC China Energy Co Ltd (CEFC China Energy) operates as energy and financial services provider. It is engaged in offering upstream oil and gas equities and interests. The company provides financial support with licenses. It is also engaged in investments and international banking businesses …
  • Bata India Limited:戦略・SWOT・企業財務分析
    Bata India Limited - Strategy, SWOT and Corporate Finance Report Summary Bata India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Torrent Power Limited:発電所・企業SWOT分析
    Torrent Power Limited - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …
  • Dubai Electricity and Water Authority:電力:M&Aディール及び事業提携情報
    Summary Dubai Electricity and Water Authority (DEWA) is an electricity and water utility. It generates, transmits and distributes electricity; and desalinates water. The authority produces electricity using gas and steam turbines, and solar PV plants. DEWA’s plants include Jebel Ali Station D, E and …
  • Veeco Instruments Inc (VECO):企業の財務・戦略的SWOT分析
    Summary Veeco Instruments Inc (Veeco) is a technology company that designs, manufacture and markets thin film and semiconductor equipment. The company offers various products and technologies which include MOCVD systems, precision surface processing system, MBE technologies, and ion beam sputtering. …
  • West Fraser Timber Co. Ltd. (WFT):企業の財務・戦略的SWOT分析
    West Fraser Timber Co. Ltd. (WFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Russel Metals Inc:企業の戦略・SWOT・財務情報
    Russel Metals Inc - Strategy, SWOT and Corporate Finance Report Summary Russel Metals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Chiesi USA Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Chiesi USA Inc (Chiesi USA), a subsidiary of Chiesi Farmaceutici S.p.A, is a specialty pharmaceutical company. It researches, develops, produces and commercializes therapies in cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. The company's product portfol …
  • Japan Airlines Co Ltd:企業の戦略・SWOT・財務情報
    Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Confluent Medical Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary Confluent Medical Technologies Inc (CMT), formerly Nitinol Devices and Components Inc is a medical device company that manufactures and markets nitinol devices and balloon catheters. The company’s products include wire, strip, sheet, tubing, and bar. Its development services include finite e …
  • Pangaea Biotech SL:企業の製品パイプライン分析2018
    Summary Pangaea Biotech SL (Pangaea) is a provider of molecular diagnostics and research and development services for cancer treatment. The company discovers and develops gene signatures and prognostic markers. Its services include molecular diagnosis, in vitro drug testing, clinical trials, biomark …
  • SK Chemicals Co Ltd (006120):企業の財務・戦略的SWOT分析
    Summary SK Chemicals Co Ltd (SK Chemicals) is a provider of chemical and pharmaceutical products. The company offers pharmaceutical drugs to treat erectile dysfunction, arthritis, peptic ulcer, gastroesophageal reflux disease (GERD), cancer and to improve blood circulation. It manufactures green che …
  • Sarah Cannon Research Institute LLC-製薬・医療分野:企業M&A・提携分析
    Summary Sarah Cannon Research Institute LLC (SCRI) is a research institute that offers integrated cancer services. The institute conducts clinical research programs for advancing cancer therapies. Its services include blood cancer network, cancer care overview, cardiovascular research, contract rese …
  • Jo-Ann Stores, Inc.:企業の戦略・SWOT・財務情報
    Jo-Ann Stores, Inc. - Strategy, SWOT and Corporate Finance Report Summary Jo-Ann Stores, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Welltower Inc:企業の戦略・SWOT・財務分析
    Welltower Inc - Strategy, SWOT and Corporate Finance Report Summary Welltower Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Mitsubishi Heavy Industries, Ltd.:企業の戦略・SWOT・財務分析
    Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆